In short Oral BPC-157 is biologically active and produces replicable results, but mechanism of absorption and distribution are distinct from the injectable form of administration
It is one of the most widely researched peptides for tissue repair, with published studies spanning tendon, ligament, muscle, bone, and gut tissue models
The SOUL trial (2025), a large-scale, double-blind, placebo-controlled study, evaluated once-daily oral semaglutide in 9,650 patients with T2DM and established atherosclerotic cardiovascular disease, chronic kidney disease, or both
Reevaluate metabolic status prior to discontinuing and restarting GLP-1 therapy, measure HbA1c, electrolytes, and fasting glucose and document any insulin requirements to assist in safe resumption